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Abstract
Glioblastoma multiforme (GBM) is the most common and malignant form of primary brain
tumors. It is highly invasive and current treatment options have not improved the survival rate over
the past twenty years. Novel approaches and technologies from systems biology have the potential
to identify biomarkers that could serve as new therapeutic targets for GBM. This study employed
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lipid profiling technology to investigate lipid biomarkers in ectopic and orthotopic human GBM
xenograft models. Primary patient cell lines, GBM10 and GBM43, were injected into the flank
and the right cerebral hemisphere of NOD/SCID mice. Tumors were harvested from the brain and
flank and proteins, metabolites, and lipids extracted from each sample. Reverse phase based high
performance liquid chromatography coupled with Fourier transform ion cyclotron resonance mass
spectrometry (LC-FTMS) was used to analyze the lipid profiles of tumor samples. Statistical and
clustering analyses were performed to detect differences. Over 500 lipids were identified in each
tumor model and lipids with the greatest fold effect in the comparison of ectopic versus orthotopic
tumor models fell predominantly into four main classes of lipids: glycosphingolipids,
glycerophoshpoethanolamines, triradylglycerols, and glycerophosphoserines. Lipidomic analysis
revealed differences in glycosphingolipid and triglyceride profiles when the same tumor was
propagated in the flank versus the brain. These results underscore the importance of the
surrounding physiological environment on tumor development and are consistent with the
hypothesis that specific classes of lipids are critical for GBM tumor growth in different anatomical
sites.

Keywords
Biomarkers; cancer; glioblastoma multiforme; lipid profiling; mass spectrometry

INTRODUCTION
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Glioblastoma Multiforme (GBM) is the most common and aggressive form of primary brain
tumor [1], and is one of the most invasive and malignant cancers described. Usually, by the
time of diagnosis a primitive subpopulation of GBM tumor cells has already migrated from
the primary tumor site and infiltrated the distant brain parenchyma, making it impossible to
cure [2]. GBM can occur at all ages but is found more frequently in older adults [3].
Although advanced diagnostic modalities, surgical techniques, and adjuvant treatment
strategies have been developed over the last 30 years, the prognosis of GBM has not
significantly changed over several decades [4]. GBM has a median survival period of
approximately 12 to 15 months from diagnosis with a two-year survival rate of only 5 – 15%
[5]. Due to the extremely aggressive nature of this cancer, current treatment options focus
primarily on extending the lifespan of the patient [6].

Author Manuscript

Systems biology approaches using genomics and proteomics have been employed to
investigate the characteristics of cancer progression and discover potential biomarkers and
new therapeutic targets. Progression of gliomas is due to genetic and epigenetic alterations,
including the loss of tumor suppressor gene function and activation of oncogenic pathways
[2]. More than 500 human GBM tumors have been sequenced and characterized [7] and
whole proteome analyses of gliomas have been performed using various human samples [8].
Lipidomics offers another important avenue to further understand the molecular mechanisms
controlling GBM progression and may yield new therapeutic targets for GBM,
complementary to the existing knowledge base generated by efforts in genomics and
proteomics.
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Lipidomics was introduced in 2003 by Han and Gross [9] and is a relatively new field [8].
Due to the membrane organizing properties of lipids, lipids play many important roles in a
cell, tissue, and organ physiology. The main biological functions of lipids are quite diverse
and critical for cell growth. Lipids function as structural components of cellular membranes
and in energy storage. Changes in cell membrane composition can affect cell signaling,
endocrine actions, membrane trafficking, and regulation of membrane-associated proteins
[10]. Involvement of lipids may be more critical in the brain function since the human brain
has the highest lipid content of all organs. The dry weight of the human brain contains 50%
to 60% lipids [11]. Recent studies have shown that lipid metabolism plays an important role
in cancer initiation and progression and is regulated by oncogenic signaling pathways [12].
The role of lipids in cancer, however, is still poorly understood due to biological and
technical difficulties [10, 13]. Most analyses of lipids in cancer have been indirect, using the
examination of enzymes in lipid biosynthesis pathways to predict the potential composition
and function of lipids within the cell. In addition, information gathered from genomics and
proteomics analyses has not been well integrated with lipidomics analyses.

Author Manuscript

We hypothesize that the lipid composition of GBM tumors is critical to tumor maintenance
and progression. As a first step in addressing this hypothesis, we utilized two types of
primary human GBM tumor cell lines (GBM10 and GBM43) in ectopic and orthotopic
xenograft mouse models and examined the lipid profile in these models. Our overall
objective was to determine if different anatomic sites (flank versus intracranial) resulted in
distinct lipid profiles. This study also represents a multidisciplinary collaborative effort to
improve the efficiency of computational pipelines. Development of appropriate
infrastructure and pipelines that provide high quality and clinically relevant tissue are
imperative to the analytics, visualization, identification, and interpretation of the “omics”
data; such studies regularly serve as case studies for pipeline advancement efforts and
identification of therapeutic biomarkers [14].

EXPERIMENTAL PROCEDURES
Cell Lines and Cell Culture
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Parental primary human GBM xenograft lines GBM10 and GBM43 were surgically
removed and provided by Dr. Jann Sarkaria (Mayo Clinic, Rochester, Minnesota). Both cell
lines are resistant to temozolomide and molecular properties have been described and
validated in low passage lines (GBM10: wildtype EGFR, wild-type p53, CDKN2A/
p16deleted, wild-type PTEN, and MGMT positive; GBM43: mutant p53, CDKN2A/
p16deleted, wild-type PTEN, and MGMT positive [15]). GBM10 and GBM43 cells were
expanded as flank tumors, harvested and maintained in 2.5% FBS for 4 days on matrigelcoated plates to remove murine fibroblasts. Cells were expanded in DMEM/F12 (Gibco
#11965 Dulbecco’s Modified Eagle Medium; 4.5g/L D-glucose and L-Glutamine) with 10%
FBS (Atlanta Biologicals Advantage FBS #S11050) for less than 2 weeks and used for set
up of intracranial models. Cells were checked for mycoplasma prior to injection into mice
and were negative. In each mouse, 3×105 cells were surgically implanted into right cerebral
hemisphere and 3 × 106 cells subcutaneously injected into the right flank. An overview of
biological sample preparation workflow is shown in (Fig. 1).
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Human GBM Xenograft Models
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NOD.CB17-Prkdcscid/J (NOD/Scid) mice were obtained from the onsite breeding colony in
the In Vivo Therapeutics Core at the Indiana University School of Medicine. Five mice were
utilized per GBM cell line. GBM10 and GBM43 cells were implanted in the right flank in
matrigel at 3 × 106 cells per mouse. Flank and intracranial tumors were implanted in the
same mice. For intracranial implantation, a digitalized stereotaxic delivery system was
utilized (David Kopf Instruments, Model 5000 microinjection unit, Tujunga, CA) as
described previously [16, 17]. For stereotaxic delivery of tumor cells, mice were placed
under general anesthesia (ip injection of 16 mg/kg xylazine and 120 mg/kg ketamine) and
positioned in the stereotaxic device. A digitalized drill assembly was used to bore a hole 0.3
mm in depth and 0.8 mm diameter in the cranium at a position 0.5 mm anterior and 1.2 mm
lateral to the bregma anatomical landmark. Tumor cells (3 × 105) in 10 μl of PBS) were
introduced slowly using a 10 μl Hamilton syringe at a depth of 3.5 mm at a rate of 2 μl/min.
Once injection was complete, the needle was kept in place for at least 5 minutes and then
slowly removed and the hole sealed with bone wax. The incision was closed with 3M
vetbond Tissue Adhesive (3M Animal Care Products). In previous validation studies,
bioluminescence imaging of xenograft tumors that express a luciferase-enhanced green
fluorescent protein (EGFP) fusion protein was performed in order to detect the tumors in the
brain and flank sites (Fig. 1B). Survival analysis using pre-death endpoint criteria was also
previously performed and the median survival is typically 35–55 days post-implantation of
tumor cells for GBM10 and 30–40 days for GBM43 in NOD/Scid mice (unpublished
observations, Wang and Pollok). Mice with flank tumors were euthanized once tumors
reached ~250 mm3. Tumors were excised and flash frozen and stored at −80°C. For mice
with intracranial tumors, the mice were observed twice daily starting at 2 weeks and prior to
reaching the pre-death endpoint were euthanized. Tumor tissue was carefully excised from
the right cerebrum and control tissue from the left cerebrum; tissues were immediately flash
frozen, and stored at −80°C until analysis.
Lipid Extraction

Author Manuscript

Sample preparation of the mouse tumors prior to mass spectrometry was performed using a
novel biomolecule extraction method to simultaneously harvest the proteins, metabolites,
and lipids in one simple and fast procedure visualized in (Fig. 2). Proteins and hydrophilic
metabolites of the mice tissues were collected and stored for the future analyses. Ten to 100
mg of in vivo mouse GBM tumor tissues were placed in a low retention 2.0 ml
microcentrifuge tubes and placed on ice. These tumor samples were mixed with 200 μl of
75% MetOH in 0.15M NaCl. Approximately 50 μl of grinding balls (ZrO; diameter ~0.5
mm) were added to each tube in order to homogenize the tumor tissues using Next Advance
Bullet Blender for two minutes. This step was repeated until the tissues were completely
homogenized. After the tissue homogenization, 20 μl of suspension from each tube was
transferred into the new 1.5 ml microcentrifuge tubes and mixed with 180 μl of 0.15M NaCl
and 1 ml of chloroform/methanol (2:1) with 0.01% BHT by vortex for two minutes, then
incubated at room temperature for 30 minutes. After the incubation, the tubes were
centrifuged for five minutes at 7,800xg and 250 μl of the lower chloroform phase of the
mixtures was transferred into the new tubes and labeled as ‘lipid’ fraction. These lipid
fractions were stored in −80°C until LC-MS analysis.
Anal Chem. Author manuscript; available in PMC 2016 April 29.
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LC-MS Analysis
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All analyses were carried out using an Agilent 1200 Series HPLC, ACE 5 C8-300 column
(2.1 × 100 mm) and linear gradient elution at a flow rate of 0.1 mL/min. Injection volume
was 4 μL. The mobile phases were composed of (A) 0.1% formic acid and 10 mM
ammonium acetate in H2O, and (B) 0.1% formic acid, 10 mM ammonium acetate in ACN/
Isopropanol (50/50; v/v). Separation of lipids was achieved at the following gradient: T=0
min: 30% B; T=1 min: 30% B; T=25 min: 100% B; T=45 min: 100% B; T=47 min: 30% B;
and T=60 min: 30% B (column re-equilibration).
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HPLC system was directly coupled to a Bruker solariX 70 Hybrid FTMS instrument
equipped with electrospray ionization source (ESI). The system was controlled by HyStar v.
3.4.8.0 software (Bruker Daltonics). MS data was collected with resolving power of 78,000
(at m/z 400) in positive or negative mode under following conditions: a capillary voltage of
(+/−) 4,500 V and an end plate offset of −500 V. The dry temperature was set at 180 °C. Dry
gas flow was maintained 4 L/min. Acquisition range was 244 – 1,800 m/z with 0.2 s ion
accumulation time.
Data Processing & Statistical Analysis

Author Manuscript

LC-MS data was converted into mzXML format using CompassXport v. 3.0.6. (Bruker
Daltonics) and processed by the mzMine v.2.10 data analysis software. Data processing
involved mass detection, chromatographic peak detection and deconvolution, gap filling,
isotopic peaks grouping, normalization and peak alignment. To determine the most
significant changes, a series of homoscedastic t-tests comparing GBM10 and GBM43 brain,
flank, and control tumors in all possible permutations was performed. The corresponding
lipids were tentatively identified using LIPID MAPS, a web-based lipid database, that uses a
textual and ontological search to identify sub class, class, and common structure of a lipid
within a variable m/z tolerance of 0.02 m/z, representing the closest catalogued lipid.
Additional structure was not elucidated. (LIPID MAPS Lipidomics Gateways, 2014).
Ethics Approval
All studies were reviewed and approved by the Indiana University Animal Care and Use
Committee (IACUC #10103) or the Purdue University Institutional Biosafety Committee
(IBC 10-003).

RESULTS
Mass Spectrometry Data Overview
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Flank and brain tumor samples derived from two primary human GBM tumor cell lines,
GBM10 and GBM43, were collected and analyzed. Lipid profiles of intracranial tumors
versus control brain tissue and intracranial tumors versus flank tumors were determined.
Among all 26 samples, which were actually extracted and analyzed, 11,218 unique positiveion mode peaks were quantified by mzMine2, representing an m/z ratio range of 244 to
1,800. To filter out insignificant peaks, a truncated data set was created by removing any
peak detected in fewer than five samples, as there were five replicate samples in each model
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grouping. This yielded 4,422 positive-ion mode peaks. A similar process for data ran in the
negative-ion mode yielded 725 unique peaks.
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Positive and negative ion mode of electrospray ionization (ESI) mass spectra was used to
distinguish different charge state distribution of the ions in macromolecules. Generally, the
positive ion mode detects the ion peaks in different protonation states [18]. As described in
the material and methods, GBM10 and GBM43 cells were implanted in the flank and right
cerebral hemisphere in each mouse on study. Sufficient sample size of 10 mg or greater was
required for analysis and was obtained in all GBM10 and GBM43 intracranial tumors and
for GBM10 flank tumors (n=5 per group). For GBM43 implanted mice, intracranial tumors
progressed faster than the flank GBM43 tumors. Therefore it was necessary to euthanize
GBM43-implanted mice at a time point when only four out of five mice had measurable
flank tumors; this was necessary in order to capture high quality intracranial GBM43 tumor
tissue for extraction and subsequent lipid analyses. At this time point, three out of four
GBM43 flank tumors were too small (1–2 mg) for extraction. Lipid profiling was completed
on the GBM43 flank tumor of sufficient size. In order to compare the tumor lipid profiles
against the normal brain lipid profiles, t-test was performed between the tumor and normal
brain profiles of GBM10 (both flank and intracranial tumors) and GBM43 (intracranial
tumors only). Of the positive-ion mode data, 368 lipids were identified to be significantly
different in lipid levels between GBM10 brain tumor tissue and the control brain tissue, 305
lipids between GBM43 brain tumor tissue and the control brain tissue, and 1926 lipids
between GBM10 flank tumor tissue and control brain tissue. Interestingly, GBM10 flank
tumor profiles showed a higher number of lipid differences compared to the brain tumor
profiles. Of the negative-ion mode data, 149 lipids were expressed at significantly different
levels between GBM10 brain tumor tissue and the control brain tissue, 233 lipids between
GBM43 brain tumor tissue and the control brain tissue, and 157 lipids between GBM10
flank tumor tissue and the control brain tissue. All these lipids had a fold effect change of
one or greater and p-value less than 0.05 from the t-test. A summary of the number of
significant lipids from the tumors propagated at different anatomical sites (flank versus
intracranial sites) and the ratio of significantly decreased and increased lipids compared to
control brain tissue is shown in Table 1. More than 500 lipid species were detected at
significantly different levels in tissues derived from the flank versus the brain, and more than
90% of these lipids were decreased in both GBM10 and GBM43 brain and flank tumors
when compared to control brain tissue. The data supports that GBM tumor tissue contains
dramatically lower levels of lipids and a different lipid composition than normal brain tissue.
Comparison of Lipid Profiles in Orthotopic Versus Ectopic Xenograft Tumors
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We next investigated differences in overall lipid composition between tumor tissues derived
from the same primary human GBM cell lines but located in distinct anatomical sites. A ttest was used to compare the lipid profiles of the all brain tumors and all flank tumors in the
same manner as the comparison between the tumor and the control profiles. 1960 lipids were
differentially expressed on the positive-ion mode profile of the flank tumor compared to the
brain tumor profiles and 206 lipids were differentially expressed on the negative-ion mode
profile (Table 2). All these lipids also had the fold effect change of one or greater and pvalue less than 0.05 based on the t-test. As shown in Table 2, the majority of these lipids
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were decreased in flank tumor tissues compared to brain tumor tissues. Differentially
expressed lipid types between brain and flank tumors support the pattern in (Fig. 3), which
expresses m/z range and different fold effect change among the brain tumors and the flank
tumors. In general, lipidomic profiles of the flank tumors of GBM expressed a greater fold
change when compared to the brain tumor profiles. The range of the lipid fold change of the
flank tumors was between approximately 20 to 30 and −35 to −20. In contrast, brain tumors
of both GBM10 and GBM43 showed a fold effect change range between −5 and 5.
Significantly Different Lipid Levels and Composition in GBM
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Most of the 500 significant lipids identified were from the lipid classes of
glycosphingolipids, glycerophosphoethanolamines, triradylglycerols,
glycerophosphocholines, and glycerophosphoserines. The thirty lipids with the highest
differences in fold effect from the comparison of GBM43 brain tumor versus the control,
GBM10 brain tumor versus the control, and flank tumor versus the control were selected
from the larger group for closer examination. These lipids fell mostly into four main lipid
classes: glycosphingolipids, glycerophosphoethanolamines, triradylglycerols, and
glycerophosphoserines. There were three compounds among top 30 significant lipids
identified from each tumor type that were identified in both positive and negative mode.
These identified lipids were Glycerophosphoglycerols (mass= 788.59, PG(38:2)/PG(38:1)),
Glycerophosphocholines/Glycerophosphoethanolamines (mass=753.55, PC(35:5)/PC(34:4),
PE(38:4)/PE(37:4)), and Glycerophosphocholines (mass=873.71, PC(42:0)). Fig. (4) is a
visual comparison of the differences in lipid concentration among the tissue types.
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The positive and negative ion profiles revealed differences in the level and composition of
lipid classes among brain and flank tumors. The positive ion profiles of
glycerophosphoserines showed decreased levels of lipids in GBM43 brain tumor tissue and
flank tumor tissue. There were only a few increased levels of lipids from GBM10 and GBM
43 tumor tissue (Fig. 4A). The negative ion profile of glycerophosphoserine did not show
any increased levels of lipids and the majority of the decreased lipids were expressed in
flank tumor tissue (Fig. 4B). Glycerophosphocholines were identified as the most frequently
identified lipids in the negative ion profiles among different tissue sources and also showed a
decreased pattern of lipid levels (Fig. 4D). Some of the flank tumor lipids from the positive
ion profiles of glycerophosphocholine were increased in comparison to the control, while the
negative ion profiles showed a similar distribution of lipids for all three tumor tissue types:
GBM10 brain tumors, GBM43 brain tumors, and all flank tumors. Glycerophosphocholines
in flank tumor tissue, however, had higher fold change than brain tumor tissue (Fig. 4C). The
profiles of glycerophosphoethanolamines had a similar trend of decreased level of lipids.
The level of glycerophosphoethanolamines in GBM10 brain tumor tissue often increased in
the positive ion profiles, while GBM43 and flank tumor tissue showed decreased fold
change (Fig. 4E). The negative ion profiles of glycerophosphoethanolamines were similar to
glycerophosphocholines (−) with decreased levels of lipids (Fig. 4F). The positive ion
profiles of triradylglycerol plot showed lipids primarily from flank tumor tissue. Some lipids
of GBM10, GBM43, and flank tumor were decreased, yet overall, the majority of the levels
of lipids that were detected from flank tumor tissue were increased (Fig. 4G). Several lipid
classes and structures were significant in both the positive and negative mode, namely
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glycerophosphoserines, glycerophosphocholines, and glycerophosphoethanolamines (Fig.
4).
Hierarchical Clustering of GBM Tumors
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For quality assurance purposes, a series of analytical approaches were employed in order to
identify any definite peculiarities associated with the results. In particular, special attention
was paid to determine whether the data for the samples demonstrated affinities consistent
with the grouping of the samples. For this purpose, an analysis using a set of clustering
algorithms, Divisive ANAlysis (DIANA) and AGglomerative NESting Hierarchical
Clustering (AGNES), was performed. Clustering is a widely adopted technique that is
unsupervised and data-dependent in that it explores the relationships between all of the
variables and not simply the targeted ones [19], and we chose clustering to avoid introducing
bias into our quality assurance efforts. To generate the clusters of the samples, m/z values
and peak intensities from MzMine2 data were compared. As a result, the output from
DIANA and AGNES showed similar patterns of clusters while these two algorithms have
distinctly different paths to generate the output [20] and have a history of use with similar
data [14].
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As is evident from (Fig. 5), these disparate approaches produced closely related results. All
the figures generated from DIANA and AGNES showed a propensity for the flank subjects
to clearly cluster away from the other tissue types while the brain and control groups
demonstrate a more closely clustered set of results. However, even in the brain and control
groups, each group tended to segregate in the expected cohorts. Based on the evidence
rendered from using DIANA and AGNES, it is likely that the results achieve the
aforementioned affinities, and accordingly the pattern mining efforts help to establish the
validity of the experimental protocol.

DISCUSSION
GBM Cell Lines and Tumor Size

Author Manuscript

Two human primary GBM cell lines, GBM10 or GBM43, were used in ectopic and
orthotopic mouse xenograft models and harvested after adequate tumor growth and
expansion. In addition to the lipid profile differences described in this study, qualitative
differences were also observed among the tumors derived from either GBM10 or GBM43.
Fig. (6) was generated to compare the tumor and normal brain tissue sizes obtained from the
different tissue types. All tissue types contained sample size of five (n=5) each. The box plot
of the tumor size shows that the size of GBM43 flank tumors was significantly smaller
compared to other tumor tissues. The analysis of lipid profiling was done in one out of the
four GBM43 flank tumors and the results were consistent with observations in the GBM10
model in that different lipid profiles exist overall in tumors propagated in the flank versus
the brain. Flank tumor tissues were also more difficult to homogenize during the extraction
procedure when compared to brain tumors and control samples. Control brain and brain
tumor tissues were mostly homogenized on the first attempt. However, most of the flank
tumors from GBM10 and GBM43 were homogenized up to five times in order to adequately
break down the tissue for subsequent analysis. Observed morphological differences in the
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tumors may be due to molecular differences between GBM10 and GBM43. Previous studies
have reported that GBM10 is wildtype for p53 but GBM43 is mutant for p53 [15]. p53 is a
tumor suppressor protein that has many functions in cancer cells, including lipid metabolism
[21].
Biological Sample Preparation for Mass Spectrometry
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The novel protocol for concurrent protein, metabolite, and lipid extraction from a single
sample was designed for a sample tissue size between 10mg and 100mg and helps address
current limitations in sample preparation of proteins, metabolites and lipids, thus resulting in
multiple benefits. First, simple and minimal procedures can save sample preparation time,
minimize degradation of metabolites, and lower sample loss during preparation period.
Secondly, the bio-molecular samples isolated from this protocol include a wide range of
lipids, metabolites and proteins, which is beneficial for untargeted omics studies. Thirdly,
due to the simple and fast sample preparation steps, the method is easily reproducible.
Systems biology approaches use a large number of samples and reproducibility is critical
[22].
Data Analysis
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Quantitative analysis of the detected lipids revealed patterns that indicate noteworthy
differences between tumor location in the mouse xenograft model of GBM. As previously
mentioned, cursory analysis using t-tests and manual identification indicated that while the
general lipid profiles of flank tumors and brain tumors appeared to be in a similar m/z range,
a comparison of lipid classes showed differences in the content of lipids. Hierarchical
clustering indicates distinct profiles of lipids in flank tumor tissues distinguished from both
brain tumor and brain control tissue, while brain tumor and brain control tissue cluster
together. This evidence may suggest that control brain and brain tumor tissues were more
closely related to each other than flank tumor tissues. The clustering output may also imply
that certain ‘background noise’ from surrounding tissue of the tumor (i.e. the variance in
lipid composition of brain tissue and flank tissue) can account for a small portion of this
clustering pattern.
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Beyond the hierarchical clustering of the data, lipid identification introduces an element of
uncertainty into the analysis. Because the mass spectrometer returned hundreds of
significantly differentially regulated lipids, many of which shared nearly identical m/z ratios,
power of manual analysis is influenced by both (1) the resolution of the LipidMaps database
and (2) the size of the database (containing just over 37,500 unique lipids). The potential of
fragmentation and creation of adducts within the ion generator, though roughly accounted
for by mzMine2, add further complication to the manual identification of lipids. The
instrument used, a Bruker 7-Tesla FT-MS, utilizing the solariX platform, provides mass
accuracy on the magnitude of greater than under one part per million, which greatly
increases the certainty of database returns on lipid identification. Likewise, the softionization of the electrospray limits fragmentation and is compatible with front-coupled
RHPLC used to separate lipids prior to analysis in the spectrometer.
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Our data showed that more than 90% of significantly identified lipids from brain and flank
GBM tumors were decreased compared to the control brain tissue. The majority of studies
exploring lipid metabolism in cancer have reported increased levels of fatty acid synthesis
[23]. Lipidomic analysis is difficult due to the specificity and complexity of lipid
composition and the lack of techniques for analysis [10]. In addition, the regulation and
complex mechanisms of lipid composition associated with cellular homeostasis are still
poorly understood [13]. There are also limitations in the use of mass spectrometry for the
structural identification of lipids. It is extremely difficult to accommodate all lipid classes
using existing current detection methods due to the number and variety of classes and
molecular species of lipids [10]. Thus most studies focus on investigating lipids indirectly by
examining the proteins involved in lipid metabolism instead of directly measuring the
composition of lipids in cancer cells. Some previous studies have examined the correlation
between membrane lipid composition and malignancy of brain tumors. Campanella and
colleagues (1992) measured membrane lipid changes among different grades of human
gliomas using HPTLC. They concluded that higher levels of malignant glioma have
significantly lower levels of total plasma membrane lipids in tumor tissues [24]. More
recently, Eberlin and colleagues (2012) used mass spectrometry to classify types of gliomas
and showed that the total lipid abundance profile of grade IV astrocytoma was lower than the
low-grade astrocytomas [25].
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Normal cells use mainly glucose and fatty acids to generate energy and fulfill the
requirements for cell growth. However, cancer cells use an altered metabolism in order to
sustain rapid growth. This altered metabolism, where cancer cells use higher levels of
glucose to generate energy by anaerobic glycolysis rather than aerobic glycolysis through
the tricarboxylic acid (TCA) cycle, is called Warburg effect [26]. As shown in (Fig. 7), the
decreased levels of lipids observed in the glioblastoma tumor tissue may suggest that GBM
depends on fatty acids as a fuel source in addition to glucose from anaerobic glycolysis.
Potentially, an increased level of lipolysis in the GBM cancer cell generates energy for
cancer cell proliferation and results in an overall decreased level of lipids detected. Other
studies have shown that fatty acids and internal structures are used as an energy source under
starvation conditions, such as in a tumor environment [27] and that the lipolytic enzyme,
monoacylglycerol lipase (MAGL), is highly upregulated in aggressive forms of cancer [23].
Inhibition of MAGL subsequently inhibited migration, invasion, and survival characteristics
of cancer cells in both in vitro and in vivo models [23].
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The central nervous system has specialized pathways for lipid synthesis and degradation
related to its specialized physiology and function [28]. Two scenarios may thus result in a
decrease in the lipid composition: lipid rich brain tissue replacing less lipid rich tumor cells
would decrease the amount of lipids overall while tumor cells would also likely exploit
normal physiological pathways related to lipid metabolism in central nervous tissue. There
are numerous reports in the literature that fatty acid synthetase (FASN) is highly upregulated
in a variety of cancers including GBM and may be a good therapeutic target [29, 30]. Future
studies will employ more robust methods of lipid identification to confirm the findings of
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this work, as well as explore the mechanism related to the decrease in lipid composition by
examining the metabolic profile and cellular composition of the tumors.
Lipid Function and Fatty Acid Oxidation
Cellular growth requires energy. High levels of lipids are critical for building membranes
and are required in rapidly proliferating cancer cells. Cancer cells can use anaerobic
glycolysis to maintain energy levels in a cancer environment through the Warburg effect
[31]. Some types of cancer also use alternative energy sources, as shown in aggressive
cancer cell lines that express higher levels of free fatty acids [32]. Research suggests that
prostate cancer does not depend on glucose for survival and instead may depend heavily on
fatty acid oxidation for cancer cell growth [33]. Fatty acid oxidation also has a critical role in
the proliferation and survival of leukemia [34]. Fatty acid oxidation has also been shown to
contribute to energy production and resistance to oxidative and nutrient stress in GBM [35].
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Recent articles [36, 37] have cautioned about the impact of experimental conditions on the
reproducibility of systems biology experiments. An important consideration for team-based
science is establishing a pipeline that ensures reproducible handling and processing of
samples and data along multiple steps. Through this study, we have established a pipeline for
the identification of molecular changes in a model system for GBM, including a
multidisciplinary team of research scientists, clinicians and statisticians with expertise in
current technologies.

CONCLUSION
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Overall, we found that GBM xenograft tumors had significantly lower levels of lipids when
compared to the normal brain tissue. Our results suggest that GBM may use fatty acid
oxidation as an additional energy source in a nutrient deprived cancer environment (Fig. 7).
It is also possible that the lower level of lipids could reflect changes in the cellular
composition of the tumor over time. Normal brain tissue has extensive cellular insulation
that includes lipid-rich myelin. As normal neuronal cells become replaced with tumor cells,
the lipid-rich myelin may decrease and subsequently the overall lipid profile in the tumor
would decrease. The profile for the flank tumors also decreased, however, and thus it is
likely that multiple factors contribute to the changes we observed in the lipids.
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Models for cancer systems are complex and have limitations that must be balanced with
experimental needs and objectives. We explored differences in tumors promoted by two
human primary tumor cell lines when placed in two distinct environments, the flank or the
brain, within a mouse model system for glioblastoma multiforme. Lipid expression profiles
and statistical clustering analysis revealed that tumors from the flank were different from
tumors in the brain, suggesting that the molecular profile of the tumors was dependent upon
the environment. The ease of homogenization during the biomolecule extraction revealed
differences in physical characteristics between the brain tumors and flanks tumors. The
physical differences were supported by molecular profile differences in classes of significant
lipids between the two xenograft tissues as flank tumors showed higher fold effects overall
when compared to brain tumors. This has implications for future studies using mouse
xenograft models to examine the molecular mechanisms that control the progression of
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GBM and the impact of potential therapeutic interventions. Studies using tumors propagated
in foreign micro-environments such as the flank while informative in initial stages of
exploration must be used with caution when testing the efficacy of anti-cancer therapies.
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Fig. 1.
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Overview of lipidomic analysis of GBM workflow. (1 A) Number of brain and flank tumors
of GBM10 and GBM43. (1 B) In vivo tumor harvest information and mouse xenograft
model validation via bioluminescence imaging. (1 C) Biomolecule extraction procedure. (1
D–E) Separation and ionization of lipid method for mass spectrometry. (2 A–B) Data
processing of mass spectrometry data using MzMine2. (2 C) Statistical analysis (2 D) Lipid
identification using the database, LIPID MAPS. (2 E) Validation of the data by performing
hierarchical clustering.
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Fig. 2.
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GBM biological sample preparation for omics study. (A) GBM10 and GBM43 cells were
expanded as flank tumors and harvested. Human GBM10 and GBM43 tumor cells were
cultured and expanded in vitro prior to implantation. (B) GBM cells were then implanted
into the flank (3×105 cells/flank) and the right cerebrum (3×106 cells/brain) of each mouse
and tumors were allowed to develop for 21 to 24 days. (C) Tumor samples from intracranial
and flank sites were harvested by excision. The tumors were flash frozen immediately and
stored in −80°C. (D) Proteins, metabolites, and lipids of GBM were extracted. The 3
fractions of the biomolecules (polar metabolite, protein, and lipid) are indicated.
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Fig. 3.
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m/z and fold effect comparison of each tissue type. The m/z and fold effect range of
differentially expressed lipids between brain and flank tumors are indicated. In general,
lipidomic profiles of the flank tumors of GBM expressed a greater fold change (between
−35and −20) when compared to the brain tumor profiles. m/z value of the identified lipids
were mostly concentrated in the range of 750 and 900.
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Fig. 4.
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Decreased trend of thirty significantly expressed lipids and lipid classes. Thirty most
significantly identified lipids from each tissue type (all flank, GBM10 brain, and GBM43
brain tumors) were plotted and grouped in four lipid species. These lipids include
glycerophosphoserines, glycerophosphocholines, glycerophosphoethanolamines, and
triradylglycerols. * symbol on the lipid structure represents the lipids that are identified as
more than one lipid classes.

Anal Chem. Author manuscript; available in PMC 2016 April 29.

Ha et al.

Page 19

Author Manuscript
Author Manuscript
Author Manuscript

Fig. 5.

Hierarchical clustering output of xenograft tissues. Two different hierarchical clustering
methods (DIANA and AGNES) were utilized to validate the data analysis method. Clusters
were created by m/z values and peak intensity from the data generated by MzMine2. Top
two graphs were generated from the positive ion mode data and bottom two graphs were
generated from the negative ion mode data.
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Fig. 6.

Tumor size comparison between different GBM tumors and control brain tissue. The box
plot represents the tumor size of different tissue types. The mass of GBM10 brain tumors
(n=5), GBM43 brain tumors (n=5), and GBM10 (n=5) tumors were similar. However, the
size of GBM43 flank tumors (n=5) from the xenograft model was significantly smaller
compared to other tumor tissues. One of GBM43 flank tumor did not grow, which counted
as 0mg. Four tumors were harvested for the lipid extraction. However, three among these
four tumors were too small for the extraction.
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Fig. 7.

Normal cells primarily use glucose to generate energy and fulfill the requirements for cell
growth. Cancer cells alter glucose metabolism and bypass the TCA cycle through the
“Warburg effect,” in order to sustain rapid cell growth. Decreased amounts of lipids, which
may occur through lipolysis in cellular organelles such as ER and Golgi, may suggest that
glioblastoma cells use fatty acids as an alternative fuel source.
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Differentially expressed significant lipids in different types of GBM tissues and control brain tissues.

Positive ion mode

Negative ion mode

GBM10 Brain

GBM43 Brain

GBM10 Flank

Over-expressed

26

21

360

Under-expressed

342 (92.9%)

284 (93.1%)

1566 (81.3%)

Over-expressed

2

0

4

Under-expressed

147 (98.7%)

233 (100%)

153 (97.5%)
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Differentially expressed significant lipids of flank tumors compared to brain tumors.
Number of lipids
Positive ion mode

Negative ion mode

Over-expressed

267

7

Under-expressed

1693

199
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